

Pharmacy Residency Program Licensing Policy

Policy

These policies and procedures are applicable to all pharmacy residents at The Brooklyn Hospital Center, including those affiliated with Long Island University

A. PGY1 Pharmacy Residents

1. Residents are required to be licensed pharmacists in New York State prior to or within 90 days of the program start date
2. Residents who are not licensed within 90 days of program start date will be put on probation as outlined in Policy R-003
3. Residents not licensed within 120 days of the program's start date must either be dismissed from the program or the resident's term of appointment extended by the number of days the resident is without licensure past the 120-day deadline
4. Resident must be licensed for at least two-thirds of the program
5. Residents not licensed within 120 days of the program's start date must take a leave of absence until licensure is obtained
 - a. Details of leave of absence are outlined in Policy R-002: Leaves of Absence

B. PGY2 Pharmacy Residents

1. Residents are required to take the New York State Pharmacy Law exam prior to the start date of the program
2. Residents are required to be licensed pharmacists in New York State prior to or within 30 days of the program start date
3. Residents who are not licensed within 30 days of program start date will be put on probation as outlined in Policy R-003
4. Residents not licensed within 90 days of the program's start date must either be dismissed from the program or the resident's term of appointment extended by the number of days the resident is without licensure past the 90-day deadline
5. Resident must be licensed for at least two-thirds of the program
6. Residents not licensed within 90 days of the program's start date must take a leave of absence until licensure is obtained
 - a. Details of leave of absence are outlined in Policy #R-002: Leave of Absences

Policy Name: Licensing		Date Approved: 1 / 1 3 / 2 0 2 3	Policy #: R-012
Written by: Briann Fischetti, PharmD, MBA, BCACP, AAHIVP		Approved by: Robert DiGregorio, PharmD, FNAP Chief Pharmacotherapy Officers	
Revised by:			
Replaces: none	Revised: 4/2024	Pages: 1	